Jan. 9, 2017
Amgen and Immatics Biotechnologies, a leading company in the field of cancer immunotherapy, have announced a research collaboration and exclusive license agreement for developing next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Amgen’s validated Bispecific T-cell Engager (BiTE®) technology with Immatics’ world-leading XPRESIDENT® target discovery and T-cell receptor (TCR) capabilities with the goal of creating novel oncology drugs. Amgen will be responsible for the clinical development, manufacturing and commercialization globally.
The intersection of immunology and oncology represents a promising and rapidly developing approach that can have a significant impact for patients with cancer. We look forward to collaborating with Immatics to translate their unique target and TCR discovery capabilities combined with Amgen’s validated BiTE® technology into novel therapies,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
Carsten Reinhardt, M.D., Ph.D., managing director and chief medical officer at Immatics, said: “We are very pleased to be entering this strategic collaboration with Amgen, which is contributing its bispecific T-cell engagers expertise, as together we look to develop novel immunotherapies that will deliver a step change in the treatment of several cancers. This collaboration also demonstrates Amgen’sconfidence in Immatics’ world-leading immune-oncology target and TCR discovery capabilities.”Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapieslast edit: 2017-01-20T15:53:51+00:00da